Cellectricon, a services provider specialising in neuroscience drug discovery, has launched the neuroinflammation research service module.
Established to expedite the development of new treatments for neurodegenerative and neuropsychiatric disorders, the Neuroinflammation Research Service has been refined and extensively tested over three years with a number of Cellectricon’s pharmaceutical and biopharma clients.
Evidence suggests that inflammatory responses in the CNS play a key role in the progression of a broad range of diseases, modulating both neurotoxic and neuroprotective activity.
Understanding the relationship between neuroinflammation and disease development is therefore crucial for the discovery of effective therapies, however until now there has been a lack of relevant in vitro models.
With long-standing experience in the development of standardised, advanced in vitro cultures, Cellectricon’s Neuroinflammation Research Service is establishing both chimeric and fully humanised in vitro disease models to accurately mimic various aspects of acute and chronic neuroinflammation.
The Neuroinflammation Research Service is already providing new insights for partner companies.
“Working in a true collaborative fashion with Cellectricon has enabled us to establish advanced in vitro platforms amenable for neuroinflammatory compound screening”, explained Dr Jonathan Levenson, CSO at FireCyte Therapeutics. “This has helped us progress our work to develop new treatments for progressive neurodegenerative diseases of the eye.”
Cellectricon will officially launch the Neuroinflammation Research Service at the 6th Neuroimmunology Drug Development Summit in Boston, US on March 25-27, 2024.
